For families weighing addiction treatment options, or for anyone in recovery facing a scheduled surgery, the result speaks to a question that comes up constantly: whether serious post-surgical pain can be managed without reaching for an opioid prescription.
What the Trial Measured
Latigo Biotherapeutics announced on July 29 that NEJM had published results from its phase 2b study of LTG-001, an oral drug that selectively blocks Nav1.8, a sodium channel that carries pain signals through peripheral nerves rather than the brain.
The trial enrolled 343 adults who reported moderate or severe pain following abdominoplasty, a surgical model researchers use because it produces predictable, substantial pain.
Participants were randomly assigned in equal groups to a high dose of LTG-001, a low dose, an opioid comparator combining hydrocodone bitartrate and acetaminophen, or a placebo. All doses were oral and given across a 48-hour window.
The primary measure was summed pain intensity difference over those 48 hours, a standard scale where higher scores indicate greater pain reduction.
The high-dose group reached 62.1, which the company reports as the strongest analgesic effect recorded in a published industry-sponsored trial using this pain model. The low dose also beat placebo, scoring 37.8.
Why the Opioid-Sparing Numbers Matter
The figure with the clearest bearing on addiction risk is not the pain score. It is how many people avoided opioids altogether.
Among patients on the high dose, 52.3% remained opioid free for the entire treatment period. In the placebo group, that figure was 22.1%. Median time to meaningful relief was about 52 minutes on the high dose and 83 minutes on the opioid comparator.
Treatment-emergent adverse events were described as mostly mild to moderate, with overall rates below those seen in the placebo arm.
Surgery remains one of the most common points of first opioid exposure in the United States. A prescription written for legitimate post-surgical pain is where a meaningful share of opioid dependence begins, particularly for people with a family history of substance use disorder or a prior period of recovery.
What This Means for Treatment Seekers
LTG-001 is investigational and not available outside of clinical trials, so nobody should expect to request it before an upcoming procedure. The practical takeaway is narrower and more immediate: non-opioid options for acute pain are advancing, and patients can ask their surgical team what alternatives exist for their specific operation.
For people already in treatment, this matters differently. Someone stabilized on medication-assisted treatment, which pairs FDA-approved medications such as buprenorphine or methadone with counseling, needs a surgical pain plan built with their prescriber involved. That conversation should happen well before the day of surgery, not in the recovery room.
Reading Industry-Funded Research Carefully
The trial was funded by Latigo, and the company designed and reported it. Independent verification through larger phase 3 studies has not yet happened.
The comparison against the opioid comparator was descriptive rather than a formal head-to-head test, which means the roughly 50% greater analgesic effect the company cites should be read as an observation from the data rather than a proven superiority claim.
Neil Singla, the company’s chief medical officer, called the publication “a significant milestone for LTG-001.” That framing is fair for a company announcement, and readers evaluating any new medication should still wait for replication before treating early results as settled.
Finding the Right Rehab
If post-surgical opioid use has turned into something harder to control, that pattern is common and treatable. Useful next steps include comparing rehab centers that treat prescription opioid dependence, confirming what your insurance covers before you call, asking whether a program offers medication-assisted treatment, and verifying a facility’s licensing and accreditation.
Rehab.com’s directory lets you filter verified treatment centers by location, level of care, and insurance accepted, so you can narrow options before speaking with anyone. Call
800-985-8516
( 
Sponsored Helpline )
to learn more about your treatment options.
